LILLY: S i no hay "talento" en casa...se busca afuera.

It’s no secret that big pharma laboratories have done a poor job discovering new medicines in recent years. There’s been a litany of high-profile failures (see here and here, for example). As a result, many inside and outside the industry now believe that innovation can no longer be limited to those labs alone — that drug makers need to look outside for help.

The announcement today that Jan Lundberg, drug discovery chief at AstraZeneca the last 10 years, will take over research and development at Lilly next year is a sign that the Indianapolis drug maker wants to look outside even more than it’s doing already. .../...

“It doesn’t really matter if it’s an in-house discovery compound or if it’s in-licensed. The key is finding compounds going all the way to the market,” he said in an interview earlier this year. Here’s the WSJ story on Lundberg’s selection and AstraZeneca’s brief announcement.

Bonus: Last year, Paul made a $1 million salary and had total compensation of $6.5 million, according to Lilly’s most recent proxy statement. (Ver...)

Tampoco se va con las manos vacias...